Technical Analysis for CALC - CalciMedica, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -5.14% | |
| Fell Below 200 DMA | Bearish | -5.14% | |
| Fell Below 50 DMA | Bearish | -5.14% | |
| Volume Surge | Other | -5.14% | |
| Calm After Storm | Range Contraction | -5.14% |
| Alert | Time |
|---|---|
| 3x Volume Pace | about 19 hours ago |
| 2x Volume Pace | about 21 hours ago |
| 1.5x Volume Pace | about 21 hours ago |
| Down 5% | about 21 hours ago |
| Down 3% | about 21 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/07/2024
CalciMedica, Inc. Description
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of calcium release-activated calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in four completed efficacy clinical trials. Auxora is in development for acute pancreatitis and asparaginase-associated pancreatitis. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Medication Inflammatory Diseases Abdominal Pain Pancreatitis Acute Pancreatitis Asparaginase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.38 |
| 52 Week Low | 2.68 |
| Average Volume | 53,231 |
| 200-Day Moving Average | 4.66 |
| 50-Day Moving Average | 4.26 |
| 20-Day Moving Average | 4.00 |
| 10-Day Moving Average | 4.02 |
| Average True Range | 0.42 |
| RSI (14) | 40.83 |
| ADX | 20.12 |
| +DI | 29.89 |
| -DI | 24.05 |
| Chandelier Exit (Long, 3 ATRs) | 4.27 |
| Chandelier Exit (Short, 3 ATRs) | 4.72 |
| Upper Bollinger Bands | 4.47 |
| Lower Bollinger Band | 3.54 |
| Percent B (%b) | -0.03 |
| BandWidth | 23.29 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.07 |
| MACD Histogram | -0.0194 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.93 | ||||
| Resistance 3 (R3) | 3.96 | 3.86 | 3.86 | ||
| Resistance 2 (R2) | 3.86 | 3.75 | 3.84 | 3.84 | |
| Resistance 1 (R1) | 3.68 | 3.68 | 3.63 | 3.65 | 3.81 |
| Pivot Point | 3.58 | 3.58 | 3.55 | 3.56 | 3.58 |
| Support 1 (S1) | 3.40 | 3.47 | 3.35 | 3.37 | 3.21 |
| Support 2 (S2) | 3.30 | 3.40 | 3.28 | 3.18 | |
| Support 3 (S3) | 3.12 | 3.30 | 3.16 | ||
| Support 4 (S4) | 3.09 |
